Search 

Ferrosan Medical Devices comprises two companies that both provide a range of innovative products used by health care professionals in the fields of surgery and diagnostics. Our technology includes Biomaterials used as haemostatic agent for surgery to control bleeding, and miniature Electromechanics used in devices for minimally invasive surgery and drug delivery.

Medxense offers accurate continuous glucose monitoring for the intensive care unit (ICU). Normalization of patient blood glucose allows hospitals to reduce mortality and patient length of stay. 

The patented sensor technology platform is the only in the field to offer both high accuracy and near-instantaneous measurements in the hypoglycemic range, necessary for safe normalization of blood glucose.

We are now looking for an investment of 3 MUSD to fund clinical trials in the 2nd half of 2014. Expected exits are trade sale or IPO.

Onbone Oy (“Onbone” or the “Company”), is a Finnish life science company founded in 2008 and based in Helsinki, Finland. Company launched it´s first product, WOODCAST® Splint intended for upper limb immobilization, in mid-2010 to Finnish markets. Since then WOODCAST® has grown into comprehensive range of casting products which are available in 11 countries across Europe with over 40 000 units shipped to date. Onbone is owned by its founders and Inveni Capital, a Finnish-German life science venture fund.

WOODCAST® products are based on significant proprietary technology and are protected by a robust patent portfolio. The Company has filed five patents covering the wood composite material, its application in orthopedics and its production.

Currently orthopedic casting is made with either plaster or glass fiber type synthetic casting products which both represent technology dating back several decades. The main problems associated with plaster and glass fiber products are messy time consuming application procedure and occupational safety risk for users posed by toxic components. However, due to lack of alternative products they are still used all over the world today.

The Company’s WOODCAST® product line represents a breakthrough technology and is the first significant cast innovation in decades with potential to gain substantial share in the highly profitable fracture treatment and orthopedic support market. WOODCAST® products are easy-to-use, non-toxic and biodegradable and have received enthusiastic responses from health care professionals all over.

For hospitals Woodcast offers increased safety and cost efficiency of the cast room operation. Additionally increasing number of hospitals have adopted environmentally sustainable product management strategies which favor the use of ecological/biodegradable alternatives when available, making Woodcast the only option.

During three first years on the market in Finland, Woodcast has been installed to 80 % of hospitals and sales have grown in three digit rate annually. Since launch in Germany in early 2013, Woodcast has been installed to dozens of hospitals and over 100 hospitals are on a waiting list to have a product trial.

The global addressable market for Woodcast products is € 1,5 billion from which 2/3 is in EU and US. Market is dominated by 3 global players; BSN Medical, 3M and Lohmann&Rauscher. Typical life cycle of a medical device start-up is to be acquired by a global player after commercial proof has been established.

Onbone is now seeking funding to finance expansion of distribution network in key markets; EU and US.

Optomeditech Oy develops patent pending breakthrough technology in the field of Intravascular Catheters. The technology uses laser light to aid in placement of the IV catheters, making the process easier, faster, safer and more reliable.

The global IV catheter market is roughly a $2B a year market that is growing 10% a year. Over 30% of first attempts to place IV catheters fail today causing significant costs and discomfort for the patients and caretakers alike. The poor placement of IV catheters is the most common cause of complaints in the hospitals. Optomeditech's product OptiVein has the technology to capture a significant portion of the IV catheter market quickly with the advantages it brings.

Optomeditech Oy has confirmed its regulatory pathway for both its CE mark and 510(k) clearance through presubmission consultation with BSI and FDA respectively and is looking to achieve CE mark by the end of Q1 2014 and 510(k) in the summer of 2014. The company is planning on entering the US market during 2015.

The company is currently conducting a clinical trial at the Helsinki University Hospital in Finland and the results have been very good to date. The clinical trial is scheduled to close at the end of August 2013.

Smartvisio care- and entertainment service runs on a cloud-based service platform which delivers communication and content services to the customers using standard audiovisual equipment – any standard TV and webcam are totally sufficient.